Brain Tumor Treatment: 2017 Update


  •  Adri Chakraborty    
  •  Jennifer Han    
  •  Cristina Faltas    
  •  Natalia Coleman    

Abstract

Malignant brain tumors are a heterogeneous group of diseases arising from different cell types that affect both adults and children. The high recurrence rate of malignant brain tumors typically is due to reappearance of focal masses, indicating that a sub population of tumor cells are insensitive to current therapies and may be responsible for reinitiating tumor growth. It is generally agreed that the resistant tumor cells are comprised of cancer stem cells or tumor-initiating cells. While brain tumor stem cells (BTSCs) were first isolated within the last decade, much of the early research has been focused on identifying the BTSC markers and therapeutic targets. The challenge however, is to translate this knowledge to therapeutics. In the current review, we survey the remedial strategies to target BTSCs, which includes diagnostic, pharmacologic, immunologic, viral, and post-transcriptional approaches.



This work is licensed under a Creative Commons Attribution 4.0 License.
  • Issn(Print): 1927-4858
  • Issn(Onlne): 1927-4866
  • Started: 2012
  • Frequency: semiannual

Journal Metrics

Google-based Impact Factor (2018): 3.94

h-index (August 2018): 8

i10-index (August 2018): 6

h5-index (August 2018): N/A  

h5-median(August 2018): N/A

(The data was calculated based on Google Scholar Citations. Click Here to Learn More. )

Contact